Cargando…

Comprehensive serial molecular profiling of an “N of 1” exceptional non-responder with metastatic prostate cancer progressing to small cell carcinoma on treatment

IMPORTANCE: Small cell carcinoma/neuroendocrine prostate cancer (NePC) is a lethal, poorly understood prostate cancer (PCa) subtype. Controversy exists about the origin of NePC in this setting. OBJECTIVE: To molecularly profile archived biopsy specimens from a case of early-onset PCa that rapidly pr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kadakia, Kunal C., Tomlins, Scott A., Sanghvi, Saagar K., Cani, Andi K., Omata, Kei, Hovelson, Daniel H., Liu, Chia-Jen, Cooney, Kathleen A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4596504/ https://www.ncbi.nlm.nih.gov/pubmed/26444865 http://dx.doi.org/10.1186/s13045-015-0204-7

Ejemplares similares

Next generation sequencing of vitreoretinal lymphomas from small-volume intraocular liquid biopsies: new routes to targeted therapies
por: Cani, Andi K., et al.
Publicado: (2016)

Comprehensive Genomic Profiling of Orbital and Ocular Adnexal Lymphomas Identifies Frequent Alterations in MYD88 and Chromatin Modifiers: New Routes to Targeted Therapies
por: Cani, Andi K., et al.
Publicado: (2016)

Aldosterone-Producing Cell Clusters Frequently Harbor Somatic Mutations and Accumulate With Age in Normal Adrenals
por: Omata, Kei, et al.
Publicado: (2017)

This Can Be as Easy as 1-2-3
por: Sanghvi, Saagar K., et al.
Publicado: (2021)

Intra-tumor Genetic Heterogeneity in Rectal Cancer
por: Hardiman, Karin M., et al.
Publicado: (2015)

Cardiac MRI and Myocardial Injury in COVID-19: Diagnosis, Risk Stratification and Prognosis
por: Sanghvi, Saagar K., et al.
Publicado: (2021)

Comparative molecular characterization of typical and exceptional responders in glioblastoma
por: Wipfler, Kristin, et al.
Publicado: (2018)

Characteristics of exceptional responders to autologous stem cell transplantation in multiple myeloma
por: Paquin, Ashley, et al.
Publicado: (2020)

Mode of action and pharmacogenomic biomarkers for exceptional responders to didemnin B
por: Potts, Malia B., et al.
Publicado: (2015)

Characteristics of exceptional responders to lenalidomide-based therapy in multiple myeloma
por: Vu, T, et al.
Publicado: (2015)

Exceptional Responder to Immunotherapy: A Rare Case of Post-HSCT DLBCL Relapse Responding to Nivolumab
por: Madabhavi, Irappa, et al.
Publicado: (2019)

Genomic analysis of exceptional responder to regorafenib in treatment-refractory metastatic rectal cancer: a case report and review of the literature
por: Korphaisarn, Krittiya, et al.
Publicado: (2017)

Comparative Molecular Analysis of Primary Central Nervous System Lymphomas and Matched Vitreoretinal Lymphomas by Vitreous Liquid Biopsy
por: Balikov, Daniel A., et al.
Publicado: (2021)

Coronary Stent Placement in an Interarterial Anomalous Right Coronary Artery: An Alternative Approach in a Multimorbid High-risk Surgical Patient
por: Simon, Erik J, et al.
Publicado: (2022)

Whole-exome sequencing of long-term, never relapse exceptional responders of trastuzumab-treated HER2+ metastatic breast cancer
por: Walsh, Naomi, et al.
Publicado: (2020)

Genomic analysis of exceptional responders to radiotherapy reveals somatic mutations in ATM
por: Ma, Jennifer, et al.
Publicado: (2016)

Sengi exceptionalism
por: Rockland, Kathleen S.
Publicado: (2014)

Case report: Metastatic urothelial cancer with an exceptional response to immunotherapy and comprehensive understanding of the tumor and the tumor microenvironment
por: Sternberg, Cora N., et al.
Publicado: (2022)

An Exceptional Responder to Nivolumab in Metastatic Non-Small-Cell Lung Cancer: A Case Report and Literature Review of Long-Term Survivors
por: Baseri, Babak, et al.
Publicado: (2019)

Case report: A persistently expanded T cell response in an exceptional responder to radiation and atezolizumab for metastatic non-small cell lung cancer
por: Coffey, David G., et al.
Publicado: (2022)

From N-of-one to series of exceptional responders: unlocking the mystery of outliers in oncology
por: Rodriguez, Julieta E., et al.
Publicado: (2023)

Molecular Characterization of a Rare Case of Bilateral Vitreoretinal T Cell Lymphoma through Vitreous Liquid Biopsy
por: Cani, Andi K., et al.
Publicado: (2021)

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: implications for sensitivity and resistance
por: Wheler, Jennifer, et al.
Publicado: (2015)

Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials
por: van la Parra, Raquel F. D., et al.
Publicado: (2016)

Immune checkpoint inhibitors in MITF family translocation renal cell carcinomas and genetic correlates of exceptional responders
por: Boilève, A., et al.
Publicado: (2018)

Circulating Tumor Cell–Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer
por: Chung, Jae-Seung, et al.
Publicado: (2019)

Rectal stromal tumor with an exceptional liver and bone metastatic locations
por: Wejih, Dougaz Mohamed, et al.
Publicado: (2019)

SAT-352 Comprehensive Genetic Analysis of Cortisol-Producing Adenomas
por: Hoxie, Jessie, et al.
Publicado: (2019)

Development and Validation of a Scalable Next-Generation Sequencing System for Assessing Relevant Somatic Variants in Solid Tumors()()
por: Hovelson, Daniel H., et al.
Publicado: (2015)

Serial monitoring of genomic alterations in circulating tumor cells of ER‐positive/HER2‐negative advanced breast cancer: feasibility of precision oncology biomarker detection
por: Cani, Andi K., et al.
Publicado: (2021)

Genomic profiling of multiple sequentially acquired tumor metastatic sites from an “exceptional responder” lung adenocarcinoma patient reveals extensive genomic heterogeneity and novel somatic variants driving treatment response
por: Biswas, Romi, et al.
Publicado: (2016)

Functional Precision Medicine Provides Clinical Benefit in Advanced Aggressive Hematologic Cancers and Identifies Exceptional Responders
por: Kornauth, Christoph, et al.
Publicado: (2022)

An exceptional vaccination policy in exceptional circumstances
por: The Lancet Infectious Diseases
Publicado: (2021)

A Case of Metastatic Adamantinoma That Responded Well to Sunitinib
por: Liman, Andrew D., et al.
Publicado: (2016)

Exceptional music pedagogy for children with exceptionalities : international perspectives
Publicado: (2016)

CMS : An exceptional load for an exceptional work site
Publicado: (2001)

Molecular and immunological features of a prolonged exceptional responder with malignant pleural mesothelioma treated initially and rechallenged with pembrolizumab
por: Minchom, Anna, et al.
Publicado: (2020)

Comprehensive serial analysis of gene expression of the cervical transcriptome
por: Shadeo, Ashleen, et al.
Publicado: (2007)

Exceptional Clinical Response to BRAF-Targeted Therapy in a Patient with Metastatic Sarcoma
por: Mitsis, Demytra, et al.
Publicado: (2015)

Exceptional responses to PARP inhibitors in patients with metastatic breast cancer in oncologic crisis
por: Cheng, Joyce M., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_95s12bjq34po0uq9m68m9ci4ur